ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements
Bal Pharma filed a Reg 32 statement confirming no deviation in its ₹2.10 Cr preferential warrant proceeds, with nothing utilised by September 30, 2026. The amount remains fully unutilised.
Bal Pharma Ltd reported revenue from operations of ₹89.9 Cr (+21.5% YoY) and net profit of ₹1.4 Cr (+100.0% YoY) for Q2 FY27.
Bal Pharma Limited informs exchanges of a board meeting on November 11, 2026, to consider unaudited standalone and consolidated results for Q2 FY2026-27. This is a prior intimation with no results figures attached yet.
Bal Pharma Ltd has filed its quarterly shareholding pattern as mandated under Regulation 31(1)(b) of the SEBI Listing Regulations.
Bal Pharma disbursed its FY25-26 final dividend of ₹1.20 per share on October 9, 2026. Dividends for shareholders with incomplete KYC or bank details have been withheld.
Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.
Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.
Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.
Bal Pharma Ltd allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, at ₹84 per warrant. This preferential issue aggregates to ₹8.4 Crore.
Bal Pharma Limited has fixed September 17, 2026, as the record date for a final dividend of Rs. 1.20 per share. Payment is scheduled for September 24.
Bal Pharma Limited has filed its Annual Report for the financial year 2025-26 along with the Notice of the 39th Annual General Meeting.
Bal Pharma Limited will hold its 39th Annual General Meeting on September 24, 2026. The record date for the final dividend is September 17, 2026.
Bal Pharma Limited clarified the 18-month tenure for utilizing net proceeds from its preferential warrant allotment. There is no change in the objects of the issue.
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ending December 31, 2025. This disclosure provides details on share distribution among promoters and public.
Bal Pharma Limited announced changes in director designations, effective October 1, 2026. These changes were approved during the board meeting held on August 12, 2026.
Bal Pharma is incorporating a new Joint Venture in the Philippines to distribute pharmaceutical products. The company will hold a 65% equity stake in this entity.
Bal Pharma Ltd reported revenue from operations of ₹88.6 Cr (+34.4% YoY) and net profit of ₹1.1 Cr (+450.0% YoY) for Q1 FY27.
Bal Pharma Ltd released the Scrutinizer's Report on postal ballot voting results regarding the proposed preferential issue of 1,000,000 warrants to the promoter.
Bal Pharma's shareholders approved a special resolution via postal ballot to issue 10,00,000 warrants to the promoter on a preferential basis.
Bal Pharma Limited has scheduled a board meeting on August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results for Q1/2026-27.
Bal Pharma Limited has provided shareholders an opportunity to submit comments or modify their votes regarding a recent corrigendum to a previously issued postal ballot notice.
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, as required by SEBI regulations.
Bal Pharma issued a corrigendum to its Postal Ballot notice, revising the preferential warrant issue price from ₹81 to ₹84 per warrant.
BAL PHARMA Ltd filed its quarterly shareholding pattern for Q2 FY2026. The filing details promoter and shareholder holdings without any monetary transaction.
Bal Pharma issued a Postal Ballot notice for shareholder approval. The agenda includes issuing 10,00,000 warrants to promoters on a preferential basis.
Bal Pharma issued a Postal Ballot Notice to approve a Rs. 8.1 Crore preferential warrant issue to its promoter. Warrants are convertible within 18 months.
Mr. Shreepada ML has commenced duties as Company Secretary and Compliance Officer. The appointment is effective from June 23, 2026.
Bal Pharma Limited recommended a final dividend of Re.1.20 per equity share for FY 2025-2026. The record date for payment will be announced later.
Bal Pharma Ltd reported revenue from operations of ₹84.1 Cr (+2.7% YoY) and net profit of ₹3.6 Cr (-33.3% YoY) for Q4 FY26.